Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
The current Gilead Sciences(GILD) stock price is $134.30, with a market capitalization of 166.72B. The stock trades at a price-to-earnings (P/E) ratio of 18.55 and offers a dividend yield of 2.36%.
On 2026-07-19, Gilead Sciences(GILD) stock moved within a range of $134.09 to $140.61. With shares now at $134.30, the stock is trading +0.2% above its intraday low and -4.5% below the session's peak.
Trading volume for Gilead Sciences(GILD) stock has reached 6.9M, versus its average volume of 6.98M.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.
GILD News
AI related stocks are drawing much of the market’s attention right now, which can leave solid, profitable companies trading on valuations that still look reason...
...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an E...
Analyst ratings
83%
of 29 ratingsMore GILD News
Gilead Sciences (GILD) is back in focus after its latest earnings report, with revenue of $6.96b up 4.4% year on year, but a significant miss on full year EPS e...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an E...
In its latest quarter, Gilead Sciences reported past revenues of US$6.96 billion, a 4.4% year-on-year increase that exceeded analysts’ expectations by 1.5% but...
Key Points Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acquisition spree this past spring. Its stock spor...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.